Close
Novotech
Jabsco PureFlo 21 Single Use

Ranbaxy launches cholesterol reducing drug in Australia

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Integrated Drug Development Consulting for Pharmaceuticals

Strategic oversight and regulatory navigation in the pharmaceutical industry rely on an integrated approach to drug development consulting, ensuring that global clinical pipelines reach the market efficiently.

Inside Cryopreservation: Key Steps and Scientific Insights

It may sound like science fiction to the layperson,...

ICON Advarra Partnership Builds Research-Ready Trial Model

ICON, a world-leading clinical research organisation, has formalised a...
- Advertisement -

Ranbaxy Australia, a subsidiary of Ranbaxy Laboratories, has introduced Atorvastatin 10mg, 20mg, 40mg and 80mg tablets after receiving approval from Therapeutic Goods Administration (TGA) in Australia.

The product is launched under the brand name Trovas in bottles and blister packs, through retail pharmacy chains. Atorvastatin, a cholesterol reducing drug, is the most prescribed statin in Australia and represents the largest patent expiry opportunity ever, in the Australian pharmaceutical market, the company said. Ranbaxy Australia managing director Alex Evans said Ranbaxy is privileged to be the first generic pany in Australia to introduce Atorvastatin under the brand name, Trovas.

Latest stories

Related stories

Integrated Drug Development Consulting for Pharmaceuticals

Strategic oversight and regulatory navigation in the pharmaceutical industry rely on an integrated approach to drug development consulting, ensuring that global clinical pipelines reach the market efficiently.

Inside Cryopreservation: Key Steps and Scientific Insights

It may sound like science fiction to the layperson,...

ICON Advarra Partnership Builds Research-Ready Trial Model

ICON, a world-leading clinical research organisation, has formalised a...

Novartis China Investment Expands R&D and Manufacturing

Novartis is stepping up its presence in China with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »